Known brand names include Humulin R, Novolin R, and Myxredlin.
A short-acting human insulin injected under the skin before meals or given by IV drip in the hospital. It lowers blood sugar in people with diabetes.
Sources: [1]
High-alert medication. Insulin, subcutaneous and IV, is on the ISMP acute care high-alert list as a class.
Sources: [1]
The label does not describe a narrow therapeutic index or direct dosing by measured blood levels of the drug.
Sources: [1]
Hypoglycemia: oral glucose for mild episodes; a glucagon product or IV glucose for coma, seizures, or neurologic impairment. Continue carbohydrates and observation because lows can recur. Correct any hypokalemia.
Sources: [1]
Sources: [1]
Sources: [1]
Doses come from the FDA label. Study tool, not for clinical decisions.
No fixed adjustment; not studied. Hypoglycemia risk is higher, so expect more frequent dose changes and glucose checks.
Sources: [1]
No fixed adjustment; not studied. Hypoglycemia risk is higher, so expect more frequent dose changes and glucose checks.
Sources: [1]
Lowers glucose by driving uptake into muscle and fat and by suppressing liver glucose production. It also blocks fat and protein breakdown and shifts potassium into cells. Subcutaneous: onset about 30 minutes, peak about 3 hours, effect ends around 8 hours. IV: onset 10 to 15 minutes, ends around 4 hours.